ClinicalTrials.gg
CompletedNCT07088471CLEARUpdated Apr 13, 2026

Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan

An observational study in Heart Failure and Reduced Ejection Fraction, sponsored by Connolly Hospital Blanchardstown. Completed at 1 site in Ireland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Connolly Hospital Blanchardstown · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
334
Ages
18 Years and older
Sex
All
01

Study summary

Heart failure is an increasingly common condition that can have a significant impact on quality of life and reduce life expectancy. In recent decades, a number of drugs have been developed specifically for this condition. One such drug, called Sacubitril/valsartan (SV) has been shown to reduce hospitalizations and prolong life expectancy of patients with heart failure. It works by reversing some of the structural and functional changes to the heart that occur in heart failure. However, not all patients respond to the drug. Further research is needed to better understand the reasons for this and predict who will benefit most from the drug.

Left atrial strain is a relatively new measurement that can be obtained using ultrasound imaging of the heart, and it provides objective information about how one of the heart's four chambers is functioning. The investigators aim to assess the effect of SV therapy on left atrial strain in patients with heart failure. The investigator's objective is to understand whether abnormal left atrial strain or changes in left atrial strain help predict response to SV therapy.

Read the detailed description

Sacubitril/valsartan (SV) improves cardiovascular outcomes in patients with heart failure and reduced ejection fraction (HFrEF) [1]. However, not all patients respond to therapy. SV therapy has been shown to promote reverse cardiac remodelling, which may contribute to its efficacy in responders [2].

Left atrial (LA) remodeling has been shown to be related to a variety of cardiovascular diseases. Until recently, the LA was only considered to act as a conduit for the left ventricle, and we now know that the LA plays a dynamic role throughout the cardiac cycle. Currently, LA volume is recommended by the European Society of Cardiology for the evaluation of LA size and remodeling [2]. Over the last decade, advancements in echocardiographic software have led to the development of novel parameters to measure LA function and remodeling. LA function is now divided into three phases: reservoir, conduit, and contractile phase.

Recently, speckle tracking on 2-dimensional echocardiography has been used to evaluate LA Strain. LA strain has been evaluated in clinical studies and has been shown to be a useful tool in the diagnosis of LA remodeling when compared to conventional methods. A recently published study from Korea has defined the reference ranges for LA strain in a healthy population [3]. Along with the reference range, the same study also looked at different determinants of LA strain [3]. LA strain by speckle tracking echocardiography is an affordable, non-invasive, pragmatic, diagnostic tool that can be performed as part of the standard 2D echocardiogram.

There have been limited studies assessing the relationship between SV therapy and LA strain. The investigators aim to evaluate the hypothesis that baseline LA strain and any changes associated with SV therapy may be a prognosticator of response to therapy in HFrEF patients.

02

Conditions studied

  • Heart Failure and Reduced Ejection Fraction

Keywords

  • left atrial strain
  • Sacubril/valsartan
  • HFrEF
  • Heart Failure
03

In context

Heart Failure, Systolic

230 studies on the registry are indexed under Heart Failure, Systolic; 50 are open to participants now.

This study's enrollment of 334 is above the median of 250 across 54 observational studies indexed under Heart Failure, Systolic.

Browse Heart Failure, Systolic studies →

Lead sponsor

Connolly Hospital Blanchardstown is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Heart Failure with reduced ejection fraction (HFrEF) patients on stable guideline-directed medical therapy prior to commencing sacubitril/valsartan (SV) will be retrospectively identified

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults diagnosed with heart Failure with reduced (HFrEF), i.e. LVEF ≤40% by Simpson's method on transthoracic echocardiography
  2. Stable guideline-directed medical therapy prior to sacubitril/valsartan (SV) initiation
  3. classes II-III symptom status
  4. Guideline-directed up-titration of SV therapy to the maximum tolerated dose
  5. Transthoracic echocardiogram and NT-proBNP prior to SV initiation and at 3 months post commencement of therapy

Exclusion criteria

Exclusion Criteria:

  1. Patients not in sinus rhythm at time of echocardiograms (precludes left atrial strain analysis)
  2. Sub-optimal echocardiographic images to allow measurement of left atrial strain
  3. Prior mitral valve intervention (left atrial strain assessment unreliable in this cohort)
  4. Severe mitral regurgitation (left atrial strain assessment unreliable in this cohort)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
334 participants (actual)
Patient registry
No

Interventions

  • DrugSacubtril/Valsartan

    Angiotensin-receptor blocker and neprilysin inhibitor therapy

06

What researchers measure

Primary outcomes

  1. Correlation between pre-therapy left atrial strain parameters on speckle-tracking echocardiography and therapy-associated changes in left ventricular ejection fraction and/or serum NT-pro BNP.

    Correlation between baseline, pre-therapy left atrial strain parameters on speckle-tracking echocardiography (TTE) with therapy-associated changes in left ventricular ejection fraction (LVEF) on TTE and serum NT-pro BNP. LVEF will be assessed on TTE using the modified Simpson's biplane method. Left atrial strain will be assessed using speckle tracking analysis with EchoPAC Software v204 (GE Vingmed Ultrasound AS, Horten, Norway). Correlation will be assessed using Spearman's rank correlation coefficients.

    Time frame: At least 3-6 months post initiation of SV therapy

Secondary outcomes

  1. Correlation between pre-therapy left atrial strain parameters and baseline left ventricular ejection fraction and serum NT-pro BNP level.

    Correlation between baseline left atrial strain values and baseline left ventricular ejection fraction and NT-pro BNP. LVEF will be assessed using the modified Simpson's biplane method. Left atrial strain will be assessed using speckle tracking analysis with EchoPAC Software v204 (GE Vingmed Ultrasound AS, Horten, Norway). Correlation will be assessed using Spearman's rank correlation coefficients.

    Time frame: At least 3-6 months post initiation of SV therapy

  2. Mean change in left atrial strain parameters pre- and post-SV therapy

    Mean change in left atrial reservoir, conduit, and booster pump values pre- and post-SV therapy. Left atrial strain will be assessed using speckle tracking analysis with EchoPAC Software v204 (GE Vingmed Ultrasound AS, Horten, Norway).

    Time frame: At least 3-6 months post initiation of SV therapy

  3. Correlation between therapy-associated changes in left atrial strain parameters and therapy-associated changes in left ventricular ejection fraction and/or serum NT pro-BNP level.

    Correlation between therapy-associated changes in left atrial strain and therapy-associated changes in left ventricular ejection fraction or NT pro-BNP. LVEF will be assessed using the modified Simpson's biplane method. Left atrial strain will be assessed using speckle tracking analysis with EchoPAC Software v204 (GE Vingmed Ultrasound AS, Horten, Norway). Correlation will be assessed using Spearman's rank correlation coefficients.

    Time frame: At least 3-6 months post initiation of SV therapy

07

Study locations

1 site
  • Connoly Hospital Blanchardstown
    Dublin, Ireland
08

References and documents

Individual participant data

Plan to share: Yes — Data can be made available upon reasonable request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in May 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2025
First posted
Jul 28, 2025
StartActual
Nov 1, 2024
Primary completionActual
May 1, 2025
CompletionActual
Aug 1, 2025
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07088471
Lead sponsor
Connolly Hospital Blanchardstown
Responsible party
Michael J Daly, MA MD PhD (Dr, Connolly Hospital Blanchardstown) — Principal investigator
First posted
Jul 28, 2025
Start date
Nov 1, 2024
Primary completion
May 1, 2025
Completion
Aug 1, 2025
Last update
Apr 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion